TITLE

The future implications and indications of anti-vascular endothelial growth factor therapy in ophthalmic practice

AUTHOR(S)
Hussain, Nazimul; Ghanekar, Yashoda; Kaur, Inderjeet
PUB. DATE
November 2007
SOURCE
Indian Journal of Ophthalmology;Nov2007, Vol. 55 Issue 6, p445
SOURCE TYPE
Academic Journal
DOC. TYPE
journal article
ABSTRACT
In the last few years anti-vascular endothelial growth factor (VEGF) therapy has changed the paradigm in the treatment of neovascular age-related macular degeneration (ARMD). Besides, its potential use in the treatment of diabetic retinopathy and other possible proliferative vascular disorders has also shown promise. Clinical trial results have shown tremendous beneficial effect of ranibizumab in ARMD. Off-label use of bevacizumab has also shown similar benefit but long-term and clinical trial results do not exist. Some of the potential questions in the use of anti-VEGF are recurring cost, possible long-term effect on physiological function of VEGF and determination of endpoint of treatment. Overall, the use of anti-VEGF therapy in ocular angiogenesis has proven to be beneficial at least now.
ACCESSION #
27260102

 

Related Articles

  • Comparison studies of anti-VEGF agents a 'global effort'. Boyle, Erin L.; Harcharek, Alexandra; Hasson, Matt; Hsvidas, Cara; Nale, Patricia; Master, Joseph; Pagnani, Michelle; Preston, Courtney // Ocular Surgery News;2/25/2011, Vol. 29 Issue 4, p25 

    The article reports on the presentation by doctor Daniel F. Martin on the comparison studies and international effort to understand the differences between the two anti-vascular endothelial growth factor (VEGF) agents, ranibizumab and bevacizumab.

  • Anti-VEGF injections may not be preferred for AMD patients with poor baseline visual acuity. Pagnani, Michelle // Ocular Surgery News;3/25/2012, Vol. 30 Issue 6, p10 

    The article reports on a study which found that for those with age-related macular degeneration and poor baseline acuity, consideration of an alternative to anti-vascular epithelial growth factor (VEGF) therapy may be warranted.

  • Novel therapy targets integrin receptors. Karageozian, Vicken // Ophthalmology Times;Oct2015, Vol. 40 Issue 17, p42 

    The article discusses the result of the clinical trial of ALG-1001 from Allegro Ophthalmics for the treatment of vitreoretinal disease. Topics covered include the comparability of ALG-1001 to that of anti-vascular endothelial growth factor agents, the reasons for targeting integrins in...

  • Silicone deposits in repackaged anti-VEGF may cause permanent IOP spikes. Kahook, Malik Y. // Ocular Surgery News;2/25/2011, Vol. 29 Issue 4, p15 

    The article focuses on the occurrence of intraocular pressure (IOP) spikes of patients that receive intravitreal injections, wherein it is said that IOP spikes is due to the silicone oil deposits that leach from the repackage vials of anti-vascular endothelial growth factor (VEGF) agents.

  • Combining anti-PDGF with anti-VEGF may improve visual acuity, reduce AMD treatment burden.  // Ocular Surgery News;7/25/2012, Vol. 30 Issue 14, Special section p1 

    The article states that the complex disease process 'Advanced age-related macular degeneration be treated by modulating two factors 'VEGF' and 'PDGF'.When anti VEGF therapy is combined with anti platelet derived growth factor aptamer it leads to a better visual outcome.The limitation of anti...

  • Ranibizumab: points to consider when using it to treat neovascular age-related macular degeneration according to EU labelling. Lyseng-Williamson, Katherine; Frampton, James // Drugs & Therapy Perspectives;Sep2013, Vol. 29 Issue 9, p268 

    Ranibizumab (Lucentis), an inhibitor of multiple vascular endothelial growth factor A isoforms, is approved for the intravitreal treatment of neovascular (wet) age-related macular degeneration (AMD). In clinical trials in patients with neovascular AMD, monthly or less frequent injections of...

  • Treat-and-extend treatment with 0.5 mg ranibizumab vs. monthly treatment with 0.5 mg ranibizumab (T-REX).  // Ocular Surgery News;5/25/2013, Vol. 31 Issue 10, p41 

    The article describes the results of a clinical trial of the safety, tolerability, and effectiveness of ranibizumab from Genentech in the treatment of patients with wet age-related macular degeneration. The study compares the efficacy of the drug when administered in the patients monthly or...

  • Eylea Snares Second Approval. Shechtman, Diana L.; Karpecki, Paul M. // Review of Optometry;12/15/2012, Vol. 149 Issue 12, p67 

    The article discusses the drug approval of the anti-vascular endothelial growth factor (VEGF) agent, Eylea for the treatment of wet age related macular degeneration (AMD) and macular edema secondary to retinal vein occlusion. It further compares the drug with another ant wet AMD drug, Lucentis....

  • Clinical trials accumulate data for novel anti-VEGF. Costa, Samantha; Hasson, Matt; Nale, Patricia; Te, Nhu // Ocular Surgery News;11/25/2014, Vol. 32 Issue 22, p22 

    The article reports on Retina Subspecialty Day of American Academy of Ophthalmology 2014 where Dr. Peter K. Kaiser talked about the vision improvement provided by an anti-vascular endothelial growth factor-agent indicated for use in wet age-related macular degeneration.

  • Molecular Partners Gets $44M for DARPin Scaffolds.  // Bioworld Week;12/21/2009, Vol. 17 Issue 51, p4 

    The article reports that Molecular Partners AG has raised 44.2 million dollars in a Series B financing round for the scaffold technology of its Designed Ankyrin Repeat Protein (DARP). Accordingly, the company will use the proceeds to fund the clinical trial of its vascular endothelial growth...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics